MDT-AP-0513
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 30
- os_event
- true
- age_years
- 37.47
- sex
- F
- new_clusters
- S2
- umap1_2d
- -1.025899002
- umap2_2d
- -10.75875152
- umap1_3d
- -2.987036164
- umap2_3d
- -0.801392012
- umap3_3d
- 6.823798293
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- E2F_TARGETS+0.470
- MYC_TARGETS_V1+0.430
- G2M_CHECKPOINT+0.410
- MITOTIC_SPINDLE+0.340
- WNT_BETA_CATENIN_SIGNALING+0.330
- HEDGEHOG_SIGNALING+0.230
- DNA_REPAIR+0.220
- GLYCOLYSIS+0.170
- APICAL_JUNCTION+0.120
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.430
- INTERFERON_GAMMA_RESPONSE-0.390
- TNFA_SIGNALING_VIA_NFKB-0.350
- ALLOGRAFT_REJECTION-0.330
- IL6_JAK_STAT3_SIGNALING-0.320
- INFLAMMATORY_RESPONSE-0.290
- COMPLEMENT-0.270
- KRAS_SIGNALING_UP-0.270
- TGF_BETA_SIGNALING-0.260
- PROTEIN_SECRETION-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-56-7823-01B-11R-2247-07 | — | cohortSQ2 | 0.915 |
| 2 | TCGA-77-8153-01A-11R-2403-07 | — | cohortSQ2 | 0.907 |
| 3 | C3N-04155 | — | cohortSQ2 | 0.906 |
| 4 | TCGA-77-8148-01A-11R-2247-07 | — | cohortSQ2 | 0.905 |
| 5 | SRR6013540 | — | cohortSQ2 | 0.891 |
| 6 | TCGA-77-8128-01A-11R-2247-07 | — | cohortSQ2 | 0.883 |
| 7 | BS_8SKZ7BRN | low-grade glioma | — | 0.874 |
| 8 | TCGA-85-8664-01A-11R-2403-07 | — | cohortMD1 | 0.874 |
| 9 | TCGA-77-A5G3-01A-31R-A27Q-07 | — | cohortSQ2 | 0.873 |
| 10 | ERR2598228 | fetal | fetal | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.330 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |
| HYPOXIA | 0.020 | Idelalisib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |